MYGN - Myriad Genetics, Inc.
After hours:
| Previous Close | 22.29 |
| Open | 22.33 |
| Bid | 22.24 x 900 |
| Ask | 23.27 x 800 |
| Day's Range | 22.18 - 23.00 |
| 52 Week Range | 13.92 - 28.18 |
| Volume | |
| Avg. Volume | 596,390 |
| Market Cap | 1.815B |
| Beta (5Y Monthly) | 1.84 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.81 |
| Earnings Date | Aug 02, 2023 - Aug 07, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 22.33 |
ZacksMyriad Genetics (MYGN) Adds New Test to Oncology Portfolio
Myriad Genetics (MYGN) expands Precise Oncology Solutions portfolio by adding a new biomarker test.
GlobeNewswireMyriad Genetics Adds Folate Receptor Alpha to Precise™ Oncology Solutions Portfolio to Expand Treatment Options for Women Living with Ovarian Cancer
Biomarker offers another companion diagnostic option to establish eligibility for FDA-approved drug ELAHERE® SALT LAKE CITY, May 24, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the addition of Folate Receptor Alpha (FRα) to its Precise™ Oncology Solutions portfolio. The new biomarker adds another companion diagnostic option for providers to help guide treatment decisions for patients with ovarian cancer. FRα i
- Investing.com
4 big analyst picks: Battered regional banks becoming buys
Investing.com -- Here is your Pro Recap of the biggest analyst picks you may have missed since yesterday: an Outperform initiation at Zions Bancorp and upgrades at KeyCorp, Greenhill, and Myriad Genetics.
ZacksHere's Why You Should Retain Myriad Genetics (MYGN) Stock Now
Myriad Genetics (MYGN) is likely to benefit from testing volumes across product segments and the latest partnerships, reflecting a positive share price movement.
- GlobeNewswire
Myriad Genetics Earns 2023 Great Place to Work Certification™
SALT LAKE CITY, May 08, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it has achieved the Great Place to Work® certification for 2023. The certification is based solely on what current employees say about their experience working at Myriad. This year, 86% of Myriad employees said the company is a great place to work – 29 percentage points higher than a typical U.S. company. “At Myriad Genetics we are committed
Simply Wall St.Myriad Genetics First Quarter 2023 Earnings: Revenues Beat Expectations, EPS Lags
Myriad Genetics ( NASDAQ:MYGN ) First Quarter 2023 Results Key Financial Results Revenue: US$181.2m (up 9.9% from 1Q...
ZacksMyriad Genetics (MYGN) Lags Q1 Earnings, Updates '23 View
Myriad Genetics (MYGN) delivers a year-over-year increase in first-quarter revenues, reflecting a positive volume improvement across the portfolio.
- Thomson Reuters StreetEvents
Q1 2023 Myriad Genetics Inc Earnings Call
Q1 2023 Myriad Genetics Inc Earnings Call
ZacksMyriad Genetics (MYGN) Reports Q1 Loss, Tops Revenue Estimates
Myriad (MYGN) delivered earnings and revenue surprises of -10.53% and 5.68%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Myriad Genetics Reports First Quarter 2023 Financial Results; Achieves 10% Revenue Growth Year-Over-Year, the Second Consecutive Quarter of Double-Digit Year-Over-Year Revenue Growth; Raises Mid-Point of 2023 Revenue Guidance Range
Highlights: First quarter testing volumes grew 21% year-over-year and 10% sequentially, excluding contributions from the SneakPeek® Early Gender DNA Test.In the first quarter: Hereditary cancer test volumes grew 24% year-over-year, the second consecutive quarter of double-digit growth year-over-year.Hereditary cancer test volumes in Women's Health grew 32% year-over-year.GeneSight® pharmacogenomics test volumes grew 31% year-over-year and 15% sequentially from the previous quarter.Prenatal test
- GlobeNewswire
Myriad Genetics to Participate in BofA Securities Healthcare Conference
SALT LAKE CITY, May 02, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it will be participating in the upcoming BofA Securities Healthcare Conference in Las Vegas, NV. Myriad management will participate in a fireside chat on Tuesday, May 9 at 3:00 p.m. PT. A live and archived webcast of the presentation can be viewed in the investor relations section of Myriad’s website at www.myriad.com. About Myriad GeneticsMy
- GlobeNewswire
Myriad Genetics to Release First Quarter Financial Results on May 3, 2023
SALT LAKE CITY, April 26, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will hold its first quarter earnings conference call on Wednesday May 3, 2023 at 4:30 p.m. ET. The company’s quarterly earnings will be released the same day after the market closes. During the call, Myriad management will provide a financial overview and business update of the company’s performance for the period ending March 31, 2023. Conference Call and
ZacksMyriad Genetics (MYGN) Gets Permit to Expand Tumor Testing
Myriad Genetics (MYGN) and Intermountain Precision Genomics receive the New York State Clinical Laboratory Permit to offer solid tumor testing to patients in all 50 U.S. states.
GlobeNewswire77% of Americans have used addictive behaviors or unhealthy coping mechanisms to manage their mental health, according to Myriad Genetics nationwide survey
Medication failure leads 45% of respondents with depression and/or anxiety to turn to unhealthy coping mechanisms Respondents may view these behaviors as addictive or unhealthy coping mechanisms, yet many still use them Respondents may view these behaviors as addictive or unhealthy coping mechanisms, yet many still use them Left to right: Depression rates increase from 2022 to 2023 & Anxiety rates increase from 2022 to 2023 Left to right: Depression rates increase from 2022 to 2023 & Anxiety rat
- GlobeNewswire
Myriad Genetics and Intermountain Precision Genomics Now Offer Solid Tumor Testing in All 50 States with Latest NY State Certification
Intermountain Precision Genomics Laboratory receives certification from NYS Department of Health Clinical Laboratory Evaluation ProgramSALT LAKE CITY, April 18, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, and Intermountain Precision Genomics, a service of Intermountain Health, are now certified to offer solid tumor testing to patients in all 50 U.S. states after receiving the New York State Clinical Laboratory Permit. This a
ZacksMyriad Genetics' (MYGN) New Pact to Boost Precision Medicine
Myriad Genetics' (MYGN) latest program will increase access to affordable genetic testing. It will also aid in identifying and elevating high-risk patient care.
- GlobeNewswire
Myriad Genetics and SimonMed® Imaging Collaborate to Advance Precision Medicine with New Genetic Risk Assessment Program
New program will increase access to affordable genetic testing while also helping to identify and elevate high-risk patient careSALT LAKE CITY, April 12, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, and SimonMed® Imaging, one of the largest independent outpatient medical imaging providers and physician radiology practices in the United States, today announced the planned launch of a new hereditary cancer assessment program th
ZacksMyriad Genetics' (MYGN) New Pact to Extend HRD Testing Access
Myriad Genetics (MYGN), together with Illumina, will seek joint HRD companion diagnostics partnerships with pharmaceutical companies globally.
- Simply Wall St.
A Look At The Intrinsic Value Of Myriad Genetics, Inc. (NASDAQ:MYGN)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Myriad Genetics fair value estimate is US$19.13 With US$22.90...
- GlobeNewswire
Illumina and Myriad Genetics expand partnership to broaden access to HRD testing in the United States
Strategic partnership offers a unique combination of diagnostic development and commercialization capabilities to the pharmaceutical industrySALT LAKE CITY, March 02, 2023 (GLOBE NEWSWIRE) -- Myriad Genetic, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, and Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced the expansion of a strategic partnership to broaden access to and availability of oncology homologous rec
- Zacks
Myriad Genetics (MYGN) Q4 Earnings Top, Gross Margin Falls
Myriad Genetics (MYGN) hereditary cancer testing volume registered strong growth in the fourth quarter. GeneSight comes up with yet another strong performance.
- Thomson Reuters StreetEvents
Q4 2022 Myriad Genetics Inc Earnings Call
Q4 2022 Myriad Genetics Inc Earnings Call
- GlobeNewswire
Myriad Genetics Applauds New Expanded Carrier Screening Practice Guidelines from NSGC
SALT LAKE CITY, March 01, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced its support for the first evidence-based expanded carrier screening (ECS) practice guidelines for reproductive risk assessment published by the National Society of Genetic Counselors (NSGC) in the Journal of Genetic Counseling. NSGC’s guidelines support equitable access and care to all patients looking to start or grow their families by rec
ZacksMyriad Genetics (MYGN) Reports Q4 Loss, Tops Revenue Estimates
Myriad (MYGN) delivered earnings and revenue surprises of 25% and 5.11%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Myriad Genetics Reports Fourth Quarter Financial Results; Fourth Quarter Revenue of $177.8 Million Grew 11% Year-Over-Year Driven by 16% Growth in Hereditary Cancer Volumes and 23% Growth in GeneSight® Volumes
Highlights: Fourth quarter testing volumes grew 26% year-over-year, and 11% year-over-year excluding the contribution from the recent acquisition of Gateway Genomics and its SneakPeek® Early Gender DNA Test. GeneSight, the company's pharmacogenomics test, grew revenue 36% for the full year 2022.Gross margin for the fourth quarter was approximately 70% reflecting underlying price stability and disciplined cost management.Diluted GAAP earnings per share (EPS) were $(0.52) and adjusted EPS were $(0
